<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929652</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-012-SPRING-C102/JS-GI2101</org_study_id>
    <nct_id>NCT04929652</nct_id>
  </id_info>
  <brief_title>Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer</brief_title>
  <official_title>Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer：An-open ，Single-arm，Multic-centers Ⅰb/Ⅱ Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Cancer Institute &amp; Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to investigate the efficacy and safety of Surufatinib Combine With&#xD;
      Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently second-line treatment is the Anti-vascular combined chemotherapy, the third line&#xD;
      standard is multi-target antivascular therapy, RIGONIVO research in three line treatment of&#xD;
      good data, but failed to further validation in the real world, one of the reasons may be the&#xD;
      third line therapy, patients physical score is relatively poor, immunotherapy to join may&#xD;
      play a role,As we know, the PS score of all effective cases in the Rigonivo study was 0.&#xD;
      Therefore, if the idea of antivascular combined immunotherapy is moved forward, it is&#xD;
      possible to achieve better efficacy,Based on the above,The objective is to investigate the&#xD;
      efficacy and safety of Surufatinib Combine With Immunotherapy and Chemotherapy for&#xD;
      Second-line Treatment in Advanced Colorectal Cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerable Dose (MTD)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Usually refers to the highest dose at which a subject's probability of developing DLT does not exceed the probability of target toxicity during the regime-specified DLT observation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>CR + PR rate according to the RECIST version 1.1 guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>To assess the efficacy of Surufatinib Combine With Immunotherapy and Chemotherapy as second-line therapy to Advanced CRC, patients by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>up to 36 months</time_frame>
    <description>OS was calculated from the date of pharmacy to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the anti-tumor activity:DCR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Disease control rate (DCR):CR + PR + SD rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Advanced CRC were given Surufatinib Combine With Immunotherapy and Chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib,Camrelizumab,Irinotecan,GM-CSF</intervention_name>
    <description>Dose climbing stage design (n=12) :&#xD;
Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed &gt; DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with &gt; developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；&#xD;
Dose expansion phase design(n=36):&#xD;
Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;&#xD;
PD-1(Camrelizumab) : 200mg, iv,D1, 3w;&#xD;
Irinotecan: 200mg/㎡, iv, D1, 3w;&#xD;
GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w.</description>
    <arm_group_label>Advanced CRC</arm_group_label>
    <other_name>Chemotherapy(Irinotecan),Immunotherapy(Camrelizumab,GM-CSF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written Informed Consent Form (ICF) prior to any study specific&#xD;
             procedures.&#xD;
&#xD;
          2. Male or female, age18-75 years.&#xD;
&#xD;
          3. Pathologically confirmed unresectable locally advanced or advanced metastatic&#xD;
             colorectal cancer .&#xD;
&#xD;
          4. First-line use of oxaliplatin in combination with fluorouracil, whether or not&#xD;
             combined with macromolecular targeted agents (Cetuximab or Bevacizumab);&#xD;
&#xD;
          5. At least 1 lesion that has not previously been irradiated, that has not been chosen&#xD;
             for biopsy during the study screening period, and that can be accurately measured at&#xD;
             Baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short&#xD;
             axis ≥ 15mm) with computerized tomography (CT) or magnetic resonance imaging (MRI),&#xD;
             whichever is suitable for accurately repeated measurements. If only one measurable&#xD;
             lesion exists, it is acceptable to be used (as a target lesion) as long as it has not&#xD;
             been previously irradiated and baseline tumour assessment scans are done at least&#xD;
             14days afar the screening biopsy is performed.&#xD;
&#xD;
          6. The patient had previously failed standard first-line systemic chemotherapy,Prior&#xD;
             adjuvant and neo-adjuvant therapy is permitted (chemotherapy, radiotherapy,&#xD;
             investigational agents) if 6 months or more have passed since completion of&#xD;
             therapy(Previous standard treatment did not include small molecule inhibitors of&#xD;
             anti-angiogenesis and Immunotherapy for PD-1 and PD-L1).&#xD;
&#xD;
          7. A WHO performance status equal to 0-1 and a minimum life expectancy of 12 weeks.&#xD;
&#xD;
          8. Inadequate bone marrow reserve or organ function, as demonstrated by any of the&#xD;
             following laboratory values:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5×109/L&#xD;
&#xD;
               2. Platelet count ≥100×109 / L&#xD;
&#xD;
               3. Hemoglobin≥9 g/dL&#xD;
&#xD;
               4. Albumin≥3g/dL&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) ≤ 2.5 × ULN if no demonstrable liver metastases&#xD;
                  or ≤ 5 × ULN in the presence of liver metastases.&#xD;
&#xD;
               6. Total bilirubin (TBL)≤ 1.5 × ULN if no liver metastases or ≤ 3 × ULN in the&#xD;
                  presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or&#xD;
                  liver metastases.&#xD;
&#xD;
               7. Creatinine≤ 1.5 × ULN concurrent with creatinine clearance ≤50 mL/min (measured&#xD;
                  or calculated by the Cockcroft-Gault equation); confirmation of creatinine&#xD;
                  clearance is only required when creatinine is ≤1.5 × ULN.&#xD;
&#xD;
          9. Females should be using adequate contraceptive measures throughout the study; should&#xD;
             not be breastfeeding at the time of screening, during the study and until 3 months&#xD;
             after completion of the study; and must have a negative pregnancy test prior to start&#xD;
             of dosing if of childbearing potential or must have evidence of non-childbearing&#xD;
             potential by fulfilling 1 of the following criteria at Screening:&#xD;
&#xD;
               1. Postmenopausal defined as age more than 50 years and amenorrheic for at least 12&#xD;
                  months following cessation of all exogenous hormonal treatments.&#xD;
&#xD;
               2. Women under 50 years old would be considered postmenopausal if they have been&#xD;
                  amenorrheic for 12 months or more, following cessation of exogenous hormonal&#xD;
                  treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone&#xD;
                  (FSH) levels in the postmenopausal range for the laboratory.Documentation of&#xD;
                  irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or&#xD;
                  bilateral salpingectomy, but not by tubal ligation. Male patients should be&#xD;
                  willing to use barrier contraception (i.e., condoms).&#xD;
&#xD;
               3. For inclusion in study, patient must provide a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with any of the following:&#xD;
&#xD;
               1. Prior treatment with Surufatinib and other small molecule antiangiogenic targeted&#xD;
                  drug therapy;.&#xD;
&#xD;
               2. Major surgery (excluding placement of vascular access) within 4 weeks of the&#xD;
                  first dose of study drug.&#xD;
&#xD;
               3. Radiotherapy with a limited field of radiation for palliation within 4 week of&#xD;
                  the first dose of study drug, with the exception of patients receiving radiation&#xD;
                  to &gt; 30% of the bone marrow or with a wide field of radiation within 4 weeks of&#xD;
                  the first dose of study drug.&#xD;
&#xD;
               4. First line treatment with irinotecan.&#xD;
&#xD;
               5. Previous experience with other anti-PD-1 antibody therapy or other PD-L1&#xD;
                  immunotherapy;&#xD;
&#xD;
          2. Patients with other malignancies, except basal cell carcinoma and carcinoma in situ..&#xD;
&#xD;
          3. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria&#xD;
             for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment, with the&#xD;
             exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.&#xD;
&#xD;
          4. Spinal cord compression or brain metastases unless asymptomatic, stable, and not&#xD;
             requiring steroids for at least 2 weeks prior to start of study treatment.&#xD;
&#xD;
          5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
             hypertension or active bleeding diatheses, which, in the Investigator's opinion, makes&#xD;
             it undesirable for the patient to participate in the trial OR which would jeopardize&#xD;
             compliance with the protocol such as active infection. Screening for chronic&#xD;
             conditions is not required.&#xD;
&#xD;
          6. Refractory nausea, vomiting, or chronic gastrointestinal diseases, inability to&#xD;
             swallow the study drug, or previous significant bowel resection that would preclude&#xD;
             adequate absorption of Surufatinib.&#xD;
&#xD;
          7. Any of the following cardiac criteria:&#xD;
&#xD;
               1. Mean resting corrected QT interval (QTc) &gt; 470 ms obtained from 3&#xD;
                  electrocardiograms (ECGs), using the screening clinic's ECG machine and&#xD;
                  Fridericia's formula for QT interval correction (QTcF).&#xD;
&#xD;
               2. Any clinically important abnormalities in rhythm, conduction, or morphology of&#xD;
                  the resting ECG (e.g., complete left bundle branch block, third-degree heart&#xD;
                  block, second-degree heart block, PR interval &gt; 250 ms).&#xD;
&#xD;
               3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic&#xD;
                  events, such as heart failure, hypokalemia, congenital long QT syndrome, family&#xD;
                  history of long QT syndrome, or unexplained sudden death under 40 years of age in&#xD;
                  first degree relatives or any concomitant medication known to prolong the QT&#xD;
                  interval.&#xD;
&#xD;
               4. Left ventricular ejection fraction (LVEF) ≤ 40%.&#xD;
&#xD;
          8. Past medical history of interstitial lung disease, drug-induced interstitial lung&#xD;
             disease, radiation pneumonitis that required steroid treatment, or any evidence of&#xD;
             clinically active interstitial lung disease.&#xD;
&#xD;
          9. Women who are breastfeeding or have a positive urine or serum pregnancy test at the&#xD;
             Screening Visit.&#xD;
&#xD;
         10. History of hypersensitivity to any active or inactive ingredient of Surufatinib or to&#xD;
             drugs with a similar chemical structure or class to Surufatinib.&#xD;
&#xD;
         11. Patients who are allergic to paclitaxel or other drugs prepared with polyoxyethyl&#xD;
             castor oil, carboplatin or other platinum containing compounds.Patients with&#xD;
             contraindications of Chemotherapy .&#xD;
&#xD;
         12. Judgment by the Investigator that the patient should not participate in the study if&#xD;
             the patient is unlikely to comply with study procedures, restrictions, and&#xD;
             requirements.&#xD;
&#xD;
         13. Any disease or condition that, in the opinion of the Investigator, would compromise&#xD;
             the safety of the patient or interfere with study assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangjun Zhu</last_name>
    <role>Study Chair</role>
    <affiliation>Jiangsu Cancer Institute &amp; Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liangjun Zhu</last_name>
    <phone>+8613770575447</phone>
    <email>zhulj98@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheng Li</last_name>
    <phone>+8613770768636</phone>
    <email>lihsh198@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changzhou NO.2 People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Jiang</last_name>
      <phone>+86 13505130679</phone>
      <email>czeyjh@njmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Institute &amp; Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu Liangjun</last_name>
      <phone>+8613905199123</phone>
      <email>zhulj98@foxmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Sheng</last_name>
      <phone>+8613770768636</phone>
      <email>lihsh198@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chunying Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ChunRong Zhu</last_name>
      <phone>+8613063870566</phone>
      <email>zcr050311@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junying Xu</last_name>
      <phone>+8613915351203</phone>
      <email>163768035@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yangzhou First People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Chen</last_name>
      <phone>+8618051062926</phone>
      <email>29008315@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Cancer Institute &amp; Hospital</investigator_affiliation>
    <investigator_full_name>Liangjun Zhu M.M.</investigator_full_name>
    <investigator_title>Ward Director of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

